Johnson & Johnson Capital Expenditures: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
JNJ Capital Expenditures Rankings
| Overall | 99th percentile | 1 of 4439 |
| Sector | 99th percentile | 1 of 510 in Healthcare |
| Industry | 96th percentile | 1 of 27 in Drug Manufacturers - Major |
JNJ Capital Expenditures Range, Past 5 Years
| Minimum | 0.00 | Mar 1987 |
| Maximum | 1.14B | Dec 2005 |
| Average | 328.96M |
About Capex
Capital expenditures are a line item from a company's statement of cash flows (click "Learn More" below for details).
Capex (short for capital expenditures) are incurred when a business spends money to purchase fixed assets or to add value to an existing fixed asset. In accounting, a capital expenditures are added to an asset account, thus increasing the value of the asset.
Examples of capital expenditures include the purchase of a new manufacturing plant, investment in server farms for tech companies, or other purchases of assets expected to help the company earn profits in the future.
Unlike other investments like research and development and marketing spending, capital expenditures are not immediately expensed. Rather, property, plant and equipment acquired using capital expenditures are usually expensed over time through the use of depreciation.
Learn More
You may also be interested in these JNJ related companies
JNJ News
News related to $JNJ, currently-0.6 pct.: 'Stryker says President and CEO MacMillan resigned' http://stks.co/2Ko9
about 3 days ago by TradeBot
about 3 days ago by TradeBot
$JNJ ... swing long started this am is starting to work ... next add area is $65.39ish
about 4 days ago by Leaf_West
about 4 days ago by Leaf_West
$JNJ failed a test of resistance, nice little short opportunity here http://chart.ly/taubwgh
about 6 days ago by optionmaster
about 6 days ago by optionmaster
long $JNJ for dvd looking for break above long long resistance in high 60's. now if they can just avoid a bad news release!
about 6 days ago by Fundies
about 6 days ago by Fundies
$JNJ Insider Sale: $29.6M of stock sold by William Weldon (Director Chairman/ceo) on February 1, 2012 http://stks.co/2F43
about 9 days ago by MarketBrief
about 9 days ago by MarketBrief
@taketheplunge $VRTX That makes little sense to me. More likely a $JNJ BO of $VRTX I would think.
about 9 days ago by SCIGUY
about 9 days ago by SCIGUY
R&D in Quebec pharma industry continues to erode $AZN $JNJ $SNY $MRK
about 10 days ago by michaelbabad
about 10 days ago by michaelbabad
$JNJ Strong Trending 66.315 from 12/27/2011 Hold 5 Days 64% Success http://stks.co/2Bxh 9:33EST #tradeideas #investing #stocks
about 11 days ago by TradeIdeas1
about 11 days ago by TradeIdeas1
Morning News: January 31, 2012 | via @EddyElfenbein http://stks.co/2APO $JNJ $AAPL $RIM
about 12 days ago by STNet
about 12 days ago by STNet
I'd say it was pretty clear that McNeil wasn't anywhere near being on the right track. No-brainer move to change the management again. $JNJ
about 13 days ago by bradloncar
about 13 days ago by bradloncar
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| JNJ | 64.60 | -0.29 | -0.45% | 176.41B |
| UNP | 111.63 | -1.17 | -1.04% | 53.93B |
| BAC | 8.07 | -0.11 | -1.34% | 81.78B |
| TRV | 59.38 | -0.51 | -0.85% | 24.51B |
| AMD | 7.05 | -0.19 | -2.62% | 4.91B |
| EBAY | 33.02 | -0.23 | -0.71% | 42.63B |
| AIG | 26.66 | -0.69 | -2.52% | 50.60B |
| NRG | 17.32 | 0.24 | 1.41% | 4.18B |
| T | 29.84 | -0.15 | -0.50% | 176.83B |
| CTB | 15.93 | -0.62 | -3.75% | 991.80M |
